≥99% HPLCPre-filled pen

SS-31 + Cardiogen (Blend)

Name: SS-31 + Cardiogen (Blend)
Brand: Dripfy
Availability: InStock

What it is?

SS-31 + Cardiogen is an investigational blend combining SS-31 (elamipretide), a mitochondria- and cardiolipin-targeting peptide studied in its own clinical trials, with Cardiogen, a short cardiac “bioregulator” peptide. Those trials concern SS-31 alone; the blend itself has no clinical-trial evidence. It sits within the mitochondrial-support and cardiac-signalling research space.

Dripfy Advantage

Cardiolipin association: SS-31 is understood to associate with cardiolipin on the inner mitochondrial membrane, a target explored for supporting mitochondrial bioenergetics.
Cardiac tissue focus: Cardiogen belongs to the peptide “bioregulator” family that has been investigated for tissue-specific signalling in cardiac cells.
Combined pathways: The blend is positioned to bring mitochondrial-membrane and cardiac-signalling research angles together under one physician-directed protocol.
Physician-directed: Any regimen is determined solely by the supervising physician.

Research & Investigational Focus

Mitochondrial bioenergetics: Explored for a possible role in supporting mitochondrial function; the clinical-trial evidence applies to SS-31 (elamipretide) alone, not to this blend.
Cardiac support research: Investigated in the context of cardiac tissue and age-associated decline (preclinical and early-stage).
Cellular resilience: Explored in relation to markers associated with oxidative and energetic stress.

Composition & Formulation

Format: Pre-filled pen
Purity: ≥99% by HPLC/MS
Supervision: Physician-directed use only

€705

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

SS-31 + Cardiogen (Blend)

Mitochondria-targeting peptide + cardiac bioregulator blend (investigational) · Pre-filled pen

D· Preliminary evidence

SS-31 (elamipretide) is thought to bind cardiolipin in the inner mitochondrial membrane, where it may help stabilise membrane structure and support electron-transport efficiency; this effect has been studied in SS-31's own clinical trials in mitochondrial disease and heart failure. Cardiogen is a short peptide from the “bioregulator” class proposed to act as a tissue-specific signalling molecule in cardiac cells, though robust human evidence is lacking. Those disease trials apply to SS-31 (elamipretide) as a single agent; this blend itself has not been studied in heart failure or mitochondrial disease and has no such clinical evidence. Combining the two is a research hypothesis rather than an established therapy.

Studied use areas

Investigated for mitochondrial bioenergetic support
Studied in the context of cardiac tissue and function
Explored for cellular resilience to oxidative/energetic stress
Positioned for age-associated mitochondrial-decline research

Safety & status

Investigational; combined human safety data are very limited
Use only under qualified physician supervision
Cardiac-targeted peptides require specialist cardiology oversight; not for use in pregnancy or breastfeeding

⚕ Clinical note: This blend is investigational and combines two compounds whose interaction has not been characterised in robust human trials, which compounds the uncertainty. It is for physician-directed research use only, is not medical advice, and is not proven to treat, cure, or prevent any condition.

Evidence: Grade D — investigational; limited human data, mainly preclinical · References: Szeto and Schiller, Pharmaceutical Research 2011; Daubert et al., Circulation: Heart Failure 2017; Khavinson, Neuroendocrinology Letters 2002